Health Care & Life Sciences » Pharmaceuticals | Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc. | Ownership

Companies that own Collegium Pharmaceutical Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Henderson Global Investors Ltd.
3,810,346
11.47%
-16,926
0.03%
06/30/2018
Macquarie Investment Management Business Trust
2,588,356
7.79%
233,598
0.08%
06/30/2018
Eventide Asset Management LLC
2,207,610
6.65%
0
1.44%
06/30/2018
BlackRock Fund Advisors
2,076,088
6.25%
231,849
0%
06/30/2018
Rock Springs Capital Management LP
1,650,000
4.97%
-270,000
1.03%
06/30/2018
Franklin Advisers, Inc.
1,402,242
4.22%
-55,977
0.02%
06/30/2018
The Vanguard Group, Inc.
1,192,060
3.59%
120,625
0%
06/30/2018
Sectoral Asset Management, Inc.
1,113,133
3.35%
-123,401
1.89%
06/30/2018
Fidelity Management & Research Co.
821,251
2.47%
0
0%
06/30/2018
Morgan Stanley Smith Barney LLC (Private Banking)
811,533
2.44%
13,066
0.01%
06/30/2018

About Collegium Pharmaceutical

View Profile
Address
100 Technology Center Drive
Stoughton Massachusetts 02072
United States
Employees -
Website http://www.collegiumpharma.com
Updated 07/08/2019
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER, and ONSOLIS. Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.